Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH9788 in Healthy Subjects
NCT06839131Phase 1Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SPH9788 with Placebo Comparator (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
SPH9788
Beyond the preview
Go deeper on NCT06839131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839131.